<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621343</url>
  </required_header>
  <id_info>
    <org_study_id>2021-04885</org_study_id>
    <nct_id>NCT05621343</nct_id>
  </id_info>
  <brief_title>New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis</brief_title>
  <acronym>TB-LIVE</acronym>
  <official_title>New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein&#xD;
      derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and&#xD;
      persistence of live mycobacteria. This inability to rule out living mycobacteria in patients&#xD;
      investigated for LTBI leads to unnecessary and potentially harmful treatment regimes all&#xD;
      around the globe.&#xD;
&#xD;
      The goal of this observational study is to identify candidate biomarkers for viable bacilli&#xD;
      in latent tuberculosis in order to decrease the use of unnecessary and ineffective antibiotic&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberculosis (TB) is the second leading cause of death due to a single infectious agent, with&#xD;
      the main burden in resource-limited settings and in vulnerable populations. It is estimated&#xD;
      that approximately 25% of the global population is infected with TB. LTBI is a condition&#xD;
      where the mycobacteria rests within the body instead of creating active disease. About half&#xD;
      of the active TB cases develop within 2 years of exposure and the other half reactivates as&#xD;
      distant as several decades post exposure. Persistence of viable bacilli is a prerequisite for&#xD;
      the reactivation of TB.&#xD;
&#xD;
      Through sampling of peripheral blood the investigators will investigate how selected&#xD;
      cytokines, enzyme activity and gene expression changes during course of treatment, 4-6&#xD;
      months, and during follow up, 1 year. These patterns will be compared to the patterns of&#xD;
      patients with: latent TB without treatment, active TB with treatment as well as healthy&#xD;
      controls. Samples will be drawn at 0, 1, 6 and 12 months, after treatment initialization when&#xD;
      applicable. Healthy controls will only be sampled once. Most of the analysis will be&#xD;
      performed on TB-antigen stimulated blood.&#xD;
&#xD;
      The investigators hypothesize that there is a substantial fraction of latent TB patients who&#xD;
      do not harbor live mycobacteria and that this is reflected in study outcome measures when&#xD;
      given treatment. Furthermore, the investigators hypothesize that this fraction of latent TB&#xD;
      patients will resemble healthy controls in terms of outcome measures whereas their&#xD;
      counterpart, latent TB patients harboring living bacteria, will not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>0-12 months</time_frame>
    <description>To determine levels of selected cytokines in supernatants of Mtb-incubated whole blood obtained from persons diagnosed with LTBI during the course of treatment, and to identify patterns of cytokine expression suggestive of bacterial eradication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>0-12 months</time_frame>
    <description>To characterize patterns of small non-coding RNA (sncRNA) expression (including microRNAs) in blood and plasma from persons diagnosed with LTBI, and to identify patterns of sncRNA expression in individuals with LTBI suggestive of bacterial eradication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of indoleamine 2, 3-dioxygenase (IDO)</measure>
    <time_frame>0-12 months</time_frame>
    <description>3. To characterize IDO activity in plasma from persons diagnosed with LTBI, and to determine whether changes in IDO activity during the course of LTBI reflect bacterial eradication</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>Persistent Infection</condition>
  <condition>Mycobacterium Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Latent TB on treatment</arm_group_label>
    <description>Treatment according to existing Swedish guidelines with:&#xD;
Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months OR Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latent TB not on treatment</arm_group_label>
    <description>Latent TB without indication for treatment OR patient who do not want to receive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active TB with treatment</arm_group_label>
    <description>Treatment according to existing Swedish guidelines. Duration and choice of antibiotic therapy depending on the condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>Healthy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals 15 years or older diagnosed with latent- or active tuberculosis or found&#xD;
        healthy as part of routine care at the out- and inpatient department of the department for&#xD;
        infectious diseases at Skåne University Hospital in Malmö, Sweden&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        LTBI (2 groups)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  latent tuberculosis: Interferon gamma (IFN-γ) &gt;0.70 IU/ml in the Quantiferon-TB Plus&#xD;
             assay&#xD;
&#xD;
          -  age 15-25 years OR high likelihood of recent TB transmission&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  active tuberculosis&#xD;
&#xD;
          -  chronic illness&#xD;
&#xD;
          -  immunosuppressive treatment&#xD;
&#xD;
          -  pregnancy (including 6 months post-partum)&#xD;
&#xD;
          -  previous treatment for either active or latent TB infection&#xD;
&#xD;
        Controls&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  age 15-25 years&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  latent- OR active tuberculosis&#xD;
&#xD;
          -  chronic illness&#xD;
&#xD;
          -  immunosuppressive treatment&#xD;
&#xD;
          -  pregnancy (including 6 months post-partum)&#xD;
&#xD;
          -  previous treatment for either active or latent TB infection&#xD;
&#xD;
        Active TB&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed with active TB&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        age &lt; 15 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Björkman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University, Faculty of Medicine, Department of Translational Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petter Holmberg, PhD student</last_name>
    <phone>+4640333108</phone>
    <email>petter.holmberg@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Björkman, Professor</last_name>
    <email>per.bjorkman@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Holmberg, PhD student</last_name>
      <phone>+4640333108</phone>
      <email>petter.holmberg@med.lu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

